
Hosted by Ted Seides
Written by a model from the transcript; not yet reviewed.
Ted Seides interviews André Perold, managing partner and chief investment officer of HighVista Strategies, a $4 billion firm rooted in endowment-style investing. They discuss the evolution of HighVista over sixteen years, shifting from a bucket-allocation model to an opportunistic search for inefficiencies across asset classes. Perold explains how the firm focuses on idiosyncratic opportunities in specialized, off-the-beaten-track markets like biotech and private credit rather than relying purely on macro forecasts or traditional asset allocation. Throughout the conversation, Perold details how they partner with small-scale specialists, manage concentration risk through diversification, and navigate a low-yield market environment.
The discussion provides valuable insights into how institutional allocators can generate alpha by shifting the unit of analysis from fund managers to specific market inefficiencies. Perold offers concrete examples from biotech drug discovery and litigation finance, explaining the mechanics of risk, return, and valuation in niche segments. Listeners get an unvarnished view of portfolio construction, active management, and the practical challenges of building enduring investment businesses.
The host opens the episode, introduces sponsors AlphaSense, Morningstar, and Juniper Square, and sets the stage for the discussion.
Ted Seides welcomes Andre Perold, outlines the episode’s focus on High Vista Strategies’ evolution and niche investment opportunities.
Andre reflects on the firm’s founding, its opportunistic, global, and diversified investment approach, and the enduring belief that alpha is scarce and transient.
The conversation moves to how High Vista expanded from a broad endowment model to targeting idiosyncratic, inefficient markets like biotech, private credit, and litigation finance.
Andre explains the importance of networking, specialist partners, and a bottom‑up approach to identify and execute on high‑conviction, low‑correlation investments.
Andre shares insights on the inefficiencies and potential of biotech, private credit corners, and litigation finance, highlighting the unique skill sets required.
The discussion turns to the limitations of short‑term active management, the value of long‑term conviction, and the role of growth versus mature sectors in current markets.
Andre outlines the dynamics of private equity, the rise of private markets, and the opportunities for early‑stage investments and secondary deals.
The hosts explore HiVista’s future direction, emphasizing deeper collaboration with specialists, direct investing, and the evolving client partnership model.
The episode concludes with personal questions about hobbies, habits, pet peeves, and advice for early‑career professionals.
The speaker emphasizes that human capital is the most valuable asset and discusses strategies for investing in and growing it.
The speaker encourages taking calculated risks, embracing failure, and using it to create opportunities and luck.
Alpha is Scarce and Transientinsight
The guest explains that alpha never stays in one place for long because it gets competed away, requiring investors to constantly skate to where the puck is going.
Shifting From Buckets to Inefficienciesstrategy
HighVista evolved from allocating capital into traditional asset class buckets to opportunistically targeting idiosyncratic opportunities in inefficient markets.
Evaluating Equity-Likeness in Portfoliosstrategy
The guest details a bottom-up and top-down process of ascribing an equity-likeness score to every investment to measure aggregate portfolio risk.
Idiosyncratic Exposure Reaches Fifty Percentdata
The firm has shifted at least fifty percent of its portfolio into idiosyncratic, specialized areas and continues to grow that allocation.
The Power of Relentless Networkingstrategy
Finding niche opportunities requires constant daily phone calls with sub-specialty experts to identify patterns and themes from the bottom up.
Biotech as a Prime Inefficiencyinsight
Biotech represents a major inefficiency because small firms handle R&D while big pharma sits out, creating mispriced binary outcomes driven by science.
Controlling Volatility Through Diversificationdata
While individual biotech stocks carry double the volatility of equities, a diversified portfolio of concentrated managers brings volatility down to mid-teens.
Litigation Finance Mechanicsstory
The guest describes funding appealed legal judgments through specialist lawyers, offering zero market correlation and potential return doubling.
“AlphaSense is the AI platform built specifically for this.”
“We absolutely believe that and we understand the inefficiency.”
“I love the outdoors. I love nature. There's something about being in, out in nature that is very tranquil.”
“I think you need to realize your most valuable asset is your human capital.”
“If you're going to fail, fail often, then you'll end up doing really well.”
“And that sort of relates to making your luck.”
“So being super close to your clients, if your clients can trust you, then you can do wonders with them.”
André Perold, the Co-Managing Partner and Chief Investment Officer of HighVista Strategies, a $4B firm with roots in endowment-style investing that searches for inefficiencies across asset classes. André was the 2nd guest on the show, where we discussed his background as a renowned investment professor at HBS and the founding of HighVista. Our second conversation covers the evolution of HighVista over the last few years. We discuss changes in the business and the firm's response by focusing on inefficient markets. We then dive into examples of opportunities in biotech, private credit and litigation finance, and close with a perspective on active management and private markets. Learn More Follow Ted on Twitter at @tseides https://twitter.com/tseides?lang=en or LinkedIn https://www.linkedin.com/in/tedseides/ Subscribe to the mailing list https://capitalallocators.com/ Access Transcript with Premium Membership https://capitalallocators.com/signup
9,909 words · 2 speakers
Speaker names marked are inferred from speaking time and the show’s known hosts — they are not voice-verified.
Page updated · transcript and summary are machine-generated